索拉非尼治疗肝细胞癌的预后评分:HAP评分的新应用
该回顾性研究利用法国和英国五中心索拉非尼治疗肝细胞癌患者数据,构建了SAP评分并与现有预后系统比较。SAP评分在训练集和验证集中均与总生存显著相关,但HAP评分在验证集中显示出比SAP评分更强的区分能力。HAP评分可能有助于临床试验分层和临床决策。
要点
- SAP评分由体力状态>0、AFP>400 ng/ml、肿瘤大小>7 cm、胆红素>17 μmol/l和 albumin<36 g/l五个变量构成。
- 训练集中SAP A、B、C级中位OS分别为14.9、7.2和2.5个月(P<0.001)。
- 验证集中HAP评分区分能力优于SAP评分,SAP评分优于BCLC和ALBI评分。
核心结论
- 在欧洲索拉非尼治疗的肝细胞癌患者中,HAP评分是最具区分能力的预后评分,可能有助于试验分层和临床决策。
研究设计与样本
- 回顾性分析法国和英国五个中心接受索拉非尼治疗的肝细胞癌患者数据,训练集来自两个中心(370例),验证集来自三个中心(468例)。
主要发现
- 训练集多变量分析中与OS独立相关的变量为:体力状态>0、AFP>400 ng/ml、肿瘤大小>7 cm、胆红素>17 μmol/l、白蛋白<36 g/l。
- 训练集中SAP评分与OS显著相关,SAP A、B、C级中位OS分别为14.9、7.2和2.5个月(P<0.001)。
- 验证集中SAP评分与OS显著相关,且区分能力优于BCLC和ALBI评分,但HAP评分区分能力优于SAP评分。
关键数值与推荐
- SAP评分:每个异常变量给1分,构建三个风险等级。
- 训练集:SAP A级中位OS 14.9个月,SAP B级7.2个月,SAP C级2.5个月(P<0.001)。
临床怎么用
- HAP评分可能有助于索拉非尼治疗肝细胞癌患者的临床试验分层和临床决策。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: No prognostic classification is currently used for patients treated with systemic therapies for Hepatocellular Carcinoma (HCC). METHODS: We retrospectively analysed data from patients treated with sorafenib for HCC from five centres in France and in the United Kingdom (UK). The training set comprised data from two centres and the validation set from three. Variables independently associated with Overall Survival (OS) in the training set were used to build the SAP (Sorafenib Advanced HCC Prognosis) score. The score was tested in the validation set, then compared with other prognostication systems. RESULTS: The training set and validation set included 370 and 468 patients respectively. In the training set, variables independently associated with OS in multivariable analysis were: performance status (PS) >0, alpha-fetoprotein (AFP) >400 ng/ml, tumour size >7 cm, bilirubin >17 μmol/l and albumin <36 g/l. The SAP score was built giving one point to each abnormal variable, and three classes were constructed. The SAP score was significantly associated with OS in the training set, with median OS of 14.9 months for SAP A, 7.2 months for SAP B and 2.5 months for SAP C (P < 0.001). In the validation set, the SAP score was significantly associated with OS, and showed greater discriminative abilities than Barcelona Clinic Liver Cancer (BCLC) and albumin-bilirubin (ALBI) scores. However, the hepatoma arterial embolisation prognostic (HAP) score showed greater discriminative abilities than the SAP score. CONCLUSION: In European patients treated with sorafenib, the HAP was the most discriminant prognostic score and may facilitate stratification in trials and inform clinical decision making.
引用
- Edeline J, Blanc JF, Campillo-Gimenez B, et al. Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score. Eur J Cancer. 2017. PMID: 28987770. doi:10.1016/j.ejca.2017.08.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。